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ABSTRACT 
 
Type 1 Diabetes mellitus (T1DM) is one of the most widespread metabolic disorders 
with epidemic dimension affecting almost 6% of the world’s population. Autoimmune 
reaction causes selective destruction of the insulin-producing β-cells within the pancreatic 
islets, leading to both acute and long-term complications. Daily insulin injections treat but no 
dot cure diabetes. Any progress in obtaining large number of transplantable insulin producing 
cells would be a major advance towards a cure for the disease. In order to create an alternative 
source of β-cells we are developing a method to transdifferentiate adult human cells to the 
beta cell phenotype by direct reprogramming mediated by forced expression of an optimized 
set of pancreas specific transcription factors. The underlying experimental rationale is that 
sequential or combinatorial ectopic expression of transcription factors can induce recipient 
cells to establish a β-cell regulatory state. We cloned a set of transcription factors known to be 
involved in pancreatic development into viral vectors and used them to transdifferentiate adult 
human cell types in conditions known to favor β-cell differentiation. 
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RESUMO 
 
A diabetes mellitus tipo 1 (DM1) é uma das alterações metabólicas mais comum a 
nível mundial, afectando quase 6% da população mundial. É uma doença auto-imune que tem 
como resultado a destruição das células β do pâncreas, produtoras de insulina. Caracteriza-se 
por hiperglicémia e insuficiência na produção de insulina, levando a complicações quer a 
curto quer a longo prazo. Não existe cura para a DM1. O único tratamento para os doentes 
com DM1 é a administração diária de insulina.  
No entanto, a administração de insulina está frequentemente associada a episódios 
graves de hipoglicémia, para além de que não previne o aparecimento das complicações 
crónicas associadas à doença, tais como a retinopatia diabética e a doença renal terminal.  
A obtenção em larga escala de células produtoras de insulina poderá ser um grande 
avanço para a cura da diabetes. Um dos métodos mais inovadores para a obtenção de células β 
é a transdiferenciação de células humanas adultas em células β produtoras de insulina, através 
da expressão ectópica de um conjunto de factores de transcrição que estão envolvidos no 
estabelecimento destas células.  
O procedimento experimental baseou-se na expressão ectópica destes factores de 
transcrição para induzir células humanas adultas a estabelecer o estadio regulatório que define 
as células β. Para tal, foi clonada uma coleção de factores de transcrição envolvidos no 
desenvolvimento pancreático em vectores virais. Estes vectores foram posteriormente 
utilizados na transdiferenciação de células humanas adultas em condições que favorecem a 
diferenciação das células β. 
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1. INTRODUCTION 
 
Diabetes mellitus (DM) is one of the most widespread metabolic disorders with 
epidemic dimension affecting almost 6% of the world’s population. In 2011, the International 
Diabetes Federation estimated that over 366 million people around the world had diabetes and 
is expected that in 2030, over 552 million people, or one adult in 10, will have diabetes 
mellitus. The global prevalence of diabetes is shifting significantly from the developed 
countries to the middle-income countries, which are acquiring a western lifestyle and dietary 
habits (Figure 1) (Kordowich et al. 2010; Nair & Aloysious 2011; Ashcroft & Rorsman 
2012). 
 
 
 
Figure 1: Worldwide diabetes prevalence in 2012. The number of people with diabetes is increasing in every 
country, with more than 371 million people worldwide being affected by the disease. Half of people with 
diabetes are undiagnosed. These estimates demonstrate the urgency for an effective prevention and treatment. 
All estimates are presented as comparative rates. Adapted from IDF Atlas fifth edition (In: 
http://www.idf.org/diabetesatlas). 
 
 
DM is a chronic disorder that results from the targeted destruction of the insulin-
producing beta(β)-cells in the pancreatic islets and it is characterized by high concentrations 
of blood glucose (hyperglycaemia). Insulin is produced and secreted by the β-cells. Cellular 
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uptake of glucose from the blood is regulated by the appropriate secretion of insulin by the 
pancreatic β-cells (Best et al. 2008; Domínguez-Bendala & Ricordi 2012a). Left untreated, 
this disease is fatal. However, even with correct medical treatment, DM patients may suffer 
from acute and long-term complications associated with the disease. The most common acute 
complication is diabetic ketoacidosis, a potentially life-threatening complication, which can 
lead to death if not treated over the period of 24 hours. Long-term complications include 
increased cardiovascular disease and accelerated atherosclerosis, hypercoagulability, 
amputation, retinopathy, nephropathy, neuropathy, dyslipidemia, microvascular damage to 
retina, with poor quality of life and death (Van Hoof et al. 2009). 
 
Diabetes is manifested in two distinct forms: an absolute deficiency of insulin (type 1) 
and a relative deficiency of insulin (type 2) diabetes. Type 2 diabetes mellitus (T2DM) is 
caused by a combination of insulin resistance in varying degrees and β-cell failure, with a 
decrease by around 50% in the β-cell mass, together leading to inadequate insulin secretion 
which is not sufficient to maintain glycaemic control (Donath & Halban 2004; Pagliuca & 
Melton 2013).  
Although most attention has focused on the increase in type 2 diabetes, a parallel rise 
in type 1 diabetes has occurred (Onkamo et al. 1999).Type 1 diabetes mellitus (T1DM) is a 
cell-specific autoimmune disorder in which the immune system of the affected individual 
attacks and destroys the pancreatic β-cells that secrete insulin in response to elevated blood 
sugar levels. It is usually (but not always) diagnosed during childhood and for that reason it is 
also referred as juvenile diabetes. T1DM affects genetically predisposed individuals.  
There are susceptibility genes that are thought to be important regulators of the 
immune response. Susceptibility is largely inherited, residing predominantly in the human 
leukocyte antigen (HLA) class II DR and DQ, and to a lesser extent in a host of other genetic 
loci called insulin-dependent diabetes mellitus susceptibility genes (IDDM).  The HLA locus 
has been known to confer 50% of the genetic susceptibility to the disease. There are other two 
candidate genes that, together, were confirmed to contribute about 15% of the risk, insulin-
VNTR (IDDM2) and CTLA-4 (IDDM12) genes (Table 1). However, more elucidations about 
the mechanism by which they alter biology to predispose to disease remains to be elucidated. 
(Anjos & Polychronakos 2004; Devendra et al. 2004; Lambert et al. 2004; Concannon et al. 
2009)  
  
	   11	  
 
    Adapted from (Denis Daneman 2006). 
 
 
T1DM can be also triggered by environmental factors that alter immune function, 
thereby initiating β-cell destruction. Putative triggers include viruses, such as congenital 
rubella or enteroviruses (but so far only congenital rubella syndrome has been associated with 
the disease), and environmental toxins, for example nitrosamines. Also, recent studies suggest 
that early exposure to cow’s milk proteins, cereals or gluten may increase the risk of Type 1 
diabetes. However, this needs to be confirmed (Devendra et al. 2004) 
Approximately 10% of all diabetics suffer from Type 1 diabetes. In addition to racial 
and regional differences involving the genetic background and environmental triggers, other 
putative reasons for the increase in T1DM frequency are the rise of childhood obesity and 
increasing sedentary lifestyle, which leads to metabolic stress by development of insulin 
resistance and inflammatory injury of β-cells, causing their functional exhaustion and 
accelerating the onset and progression of the disease (The Diabetes Control and 
Complications Trial Research Group 1993; Yoon & Jun 2005; Denis Daneman 2006; 
Gangaram-Panday et al. 2007; Pozzilli et al. 2011).  
The abnormal activation of the T-cell-mediated immune system in susceptible 
individuals leads to an inflammatory response within the islets (insulitis) as well as to a 
humoral response with production of antibodies to β-cell antigens (Devendra et al. 2004).  
This chronic process leads to selective destruction of the insulin-producing β-cells within the 
pancreatic islets. The resulting complete deficit of insulin, the main hormone regulating 
glucose as well as lipid and protein metabolism, causes hyperglycaemia (The Diabetes 
Chromosome Candidate genes/markers
IDDM1 HLA DR/DQ regionMajor role in presentation of peptides to T cells
IDDM2 Insulin-VNTR Protection associated with greater thymic insulin message
IDDM12 CTLA-4, CD28 Related to T-cell activation, thyroid autoimmunity
For many of those not listed (IDDM 3-11, 13-17), either the responsible gene remains 
unidentified or the gene function is uncertain in relation to type 1 diabetes. 
6p21.31
11p15.5
2q33
Table 1 - Important susceptibity loci for type 1 diabetes. 
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Control and Complications Trial Research Group 1993; Zimmet et al. 2001; Steiner 2006; 
Van Hoof et al. 2009). 
Because type 1 diabetic patients are unable to produce insulin, it is necessary to treat 
them with exogenous insulin in a daily basis, in order to maintain blood glucose levels within 
acceptable limits. Currently, insulin therapy is the treatment of choice for these patients, 
associated with specific diet and physical exercise programs (Zimmet et al. 2001; D Daneman 
2006; Gangaram-Panday et al. 2007).  
However, intensive insulin treatment has been associated with increasing severe 
hypoglycaemia, which is a frequent side effect of insulin therapy and a major obstacle to 
achieve normal glucose levels, leading to deterioration of glucose control and cardiovascular 
accidents. Up to 10-20% of long-standing T1DM patients have unstable metabolic control and 
hypoglycaemic episodes, which taken together can lead to progressive complications, as 
mentioned before. Trying to achieve glycaemic control in between narrow ranges is 
important, as the mortality rate in such individuals is high (McCrimmon 2008). 
Whole pancreas transplant/Pancreas transplant alone (PTA) counteract many of the 
difficult aspects of type 1 DM, alleviating insulin-dependence, with improvement of 
glycaemic control, reduction of severe hypoglycaemic episodes, thus improving the quality of 
life of the patients and preventing long-term diabetic complications (The Diabetes Control 
and Complications Trial Research Group 1993; Ryan et al. 2006; Collombat et al. 2010). 
Nevertheless, the acute risks of pancreas transplant alone (PTA) include rejection, graft 
pancreatitis, intra-abdominal infection, venous or arterial thrombosis, and others (Gruessner 
& Sutherland 2005).There are also the long-term risks of immunosuppression with a possible 
increased risk of death. Thus, a PTA should be considered only if there are major concerns 
with glycaemic control not amenable to current therapy, since it has risks inherent to any 
major surgery (Humar et al. 2000; Becker & Odorico 2001; Ryan et al. 2006).  
β-cell replacement therapy by allogeneic pancreatic islet transplantation might be a 
less invasive and safer option than pancreas transplantation, since the latter has a higher risk 
of perioperative morbidity and mortality. The islet transplant is a simpler procedure that 
involves percutaneous cannulation of the portal vein. Still, there is an associated risk of 
bleeding, puncture of the gallbladder, or abdominal pain (Ryan et al. 2002).  
A final problem is the scarcity of pancreatic donors, which increases the imbalance 
between supply and demand. Thus, the protocol for islet transplantation remains far from 
ideal, as it requires a large supply of cadaveric material to treat a single patient (Ryan et al. 
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2006; Best et al. 2008; Ben-Othman et al. 2013a). Limited organ availability and the 
transplant associated immunosuppressive therapies prevent transplantation from becoming a 
widely available treatment option (Domínguez-Bendala & Ricordi 2012b).  
For that, other alternatives must be found in order to efficiently treat the consequences 
of T1DM, but also type 2 diabetes, since both diseases will eventually result in a loss and/or 
insufficient number of β-cells (Kordowich et al. 2010; Collombat et al. 2010; Ben-Othman et 
al. 2013a).  
In search for alternative treatments for T1DM, researchers are trying to find different 
sources of β-cells. An interesting option could be the generation of pancreatic β-cells from 
stem cells, progenitor or other cell subtypes, which represents one of the most promising 
research fields for β-cell replacement therapy. β-cells are an attractive case for cell 
replacement therapy because only a single cell type is missing and replacement can occur in 
non-endogenous sites, a surgical advantage since cells can be placed subcutaneously in 
minimal invasive surgeries. 
 However, it is still not known how to generate these fully functional β-cells. 
Therefore, to design rational protocols allowing the in vitro or in vivo generation of β-cells, it 
is important to gain further knowledge about the molecular mechanisms underlying the 
development of embryonic and adult β-cells, in vivo (Kordowich et al. 2010). A deeper 
understanding of the normal developmental processes that occur during pancreas formation, 
(transcription factors, extracellular signals, signaling pathways) is the key to understand cell 
fate decisions that determine whether or not progenitor cells will become islets and it is of 
greatest importance to the engineering of other cell types into β-cells (Van Hoof et al. 2009; 
Rieck et al. 2012; Ben-Othman et al. 2013a; Pagliuca & Melton 2013).  
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1.1 Pancreas Development 
 
Most of our knowledge on pancreatic development comes from studies in model 
organisms, such as the mouse model. In fact, the most important molecular players are highly 
conserved between mouse and human. 
Pancreas development can be divided in four main stages: 1) formation of definitive 
endoderm, 2) foregut differentiation, 3) endocrine specification, and 4) β-cell differentiation 
(Figure 2) (Domínguez-Bendala 2009; Guney & Gannon 2009; Van Hoof et al. 2009). 
 
Figure 2: Critical developmental milestones for β-cell development. Pluripotent stem cells first acquire the 
identity of one of the three germ layers; pancreatic cells arise from the endodermal layer. A subset of endoderm 
is specified by Pdx1 expression to become pancreatic endoderm, which will further differentiate into acinar, 
ductal or endocrine fate. Endocrine progenitors express Ngn3 and consequently differentiate into the five 
hormone-expressing cell types within the islets, which will depend on which transcription factors are being 
expressed. Some of the most relevant transcription factors are listed. Ins, Insulin; Ccg, Glucagon; Sst, 
Somatostatin; Ppy, Pancreatic polypeptide; Ghrl, Ghrelin. Adapted from (Pagliuca & Melton 2013). 
 
 
A variety of studies in the mouse model provided further insight on the morphological 
aspects of early pancreas formation.  
Gastrulation defines the cellular organization in the three germ layers: ectoderm, 
mesoderm and endoderm. Closure of anterior endoderm will form the primitive gut tube, 
which will further develop into the foregut, the midgut and the hindgut. Several organs derive 
from endoderm, such as pancreas, liver, thyroid, lungs and intestine (Deutsch et al. 2001; Best 
et al. 2008). In the mouse, the gut tube becomes evident at embryonic day (e) e8.5-e9.0, after 
closure of anterior endoderm. The pancreas arises from two different embryonic growths of 
the dorsal and ventral regions of the foregut endoderm (Slack 1995). In contrast, the liver 
Mesoderm
Ectoderm Liver
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Duct Acinar
Pluripotent Endoderm Pancreatic
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Endocrine
progenitorAlb1 Cdx2 Sox9 Ptf1a
Sox17
FoxA2
Pdx1
Nkx6.1
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Sox9
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Ppy
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PP-cells
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develops from the ventral region, next to the ventral pancreas (Zaret 1996; Wells & Melton 
1999; Zaret 2000). 
The dorsal bud develops in proximity to the notochord (possibly mediated by a FGF 
or activin) and later to the dorsal aortic endothelial cells, that together provide inductive 
signals for early bud formation (Kim et al. 1997; Lammert et al. 2001). It is characterized by a 
robust expression of Pdx1 at e9.0, when the embryo turns and the endoderm is still closely 
associated with the notochord. The ventral bud develops from two lateral areas of the 
endoderm at the same level. However, the ventral and dorsal pancreas develop by means of 
different mechanisms due to different tissue formation context, i.e., opposing to the dorsal 
pancreas, the ventral pancreas will develop in close association with presumptive hepatic and 
bile duct endoderm. Despite that, communication between ventral pancreas and liver has not 
been reported, it is possible that interaction between these structures might be important for 
pancreas morphogenesis (Wells & Melton 1999; Jørgensen et al. 2007; Stanger & Hebrok 
2013). 
At embryonic day (e) 9.5 in the mouse (or gestational day 25 in humans), the dorsal 
and the ventral buds begin to evaginate: the pancreatic buds elongate and branch, sending 
finger-like epithelial protrusions into the surrounding mesenchyme with subsequent branching 
morphogenesis (Jørgensen et al. 2007; Guney & Gannon 2009). Lineage tracing studies have 
shown that early pancreatic buds are composed of multipotent pancreatic progenitor cells that 
give rise to exocrine, endocrine and duct cells (Zhou et al. 2007). 
By e10.5, insulin and glucagon-positive cells can be detected in the primitive buds, 
but they do not express markers of mature β- and α- cells, respectively and it is thought that 
they are not the precursors of mature islets (Herrera 2000).  
At e12.0, the dorsal and ventral buds start to rotate and give rise to one interconnected 
organ (Jørgensen et al. 2007; Guney & Gannon 2009). 
At e13 (until e16 in the mouse), dramatic changes occur in the cellular architecture of 
the pancreas. A process named secondary transition initiates, during which a remarkable 
increase in the number of endocrine cells budding from the ductal epithelium is detected, 
particularly β-cells. Most of the hormone-expressing cells that will contribute to the formation 
of the mature islets begin to emerge at this stage, except for the early glucagon-positive 
endocrine cells, observed since e9.5 (Jørgensen et al. 2007; Oliver-Krasinski & Stoffers 
2008). At the same time, rapid branching morphogenesis takes place, as well as acinar cell 
differentiation with increases in acinar enzyme gene expression (Gittes 2009). 
	   16	  
  To note that, despite most of the important molecular players are highly conserved 
between mouse and human, there are some differences in the overall morphology of the 
mature pancreas between humans and mice (Table 2). A brief example is the obvious 
difference in duration of pancreas formation. Also, in contrast to the organized mouse islets, 
that contain a large core of β-cells surrounded by a layer of α-cells and other endocrine cells, 
the human endocrine cells that compose islets have a more random pattern (Wieczorek et al. 
1998). 
 
 
 
            Adapted from (Domínguez-Bendala 2009) 
 
 
 
 
 
 
 
 
 
Mouse developmental stage Event Human developmental stage
E8.5-9.5
Initiation of pancreatic development; 
evagination from the primitive foregut; 
Pdx1 expression
3-4 w.p.c
E9.5-10.5 Immunodetection of glucagon expression 8.5 w.p.c
E10.5-11.5 Immunodetection of insulin expression 7 w.p.c
E12.5 The two pancreatic buds fuse at the base 8 w.p.c
E13.5-14.5 onward
Formation of acini from ducts
Initiation of secondary transition
Immunodetection of somatostatin expression
8.5 w.p.c onward
E16.5-18.5
Immunodetection of PP expression
Islet formation
10 w.p.c
12-13 w.p.c.
Table 2 - Correspondence between human and mouse pancreatic development 
(E - embryonic day; w.p.c - weeks postconception) 
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1.2 Anatomy of the Mature Pancreas  
 
1.2.1 The β-cell 
 
The mature pancreas is a solid glandular organ in the gastrointestinal tract and plays a 
crucial role in maintaining nutritional homeostasis through synthesis and secretion of 
hormones and enzymes (Kordowich et al. 2010). Three functionally distinct tissue types 
compose the mature pancreas: acinar, ductal and endocrine.  
The exocrine pancreas consists of acinar cells that secrete digestive enzymes, such as 
amylases, lipases, proteases and nucleases into the pancreatic duct. Acinar cells also produce 
bicarbonate ions and electrolytes, which together with exocrine enzymes, are transported 
through the main duct into the duodenum, contributing to the food processing and digestion 
(Githens et al. 1994). Acinar and duct cells represent approximately 98% of the total organ 
mass. Endocrine cells represent less than 2% of the pancreatic tissue regulate nutrient 
metabolism and glucose homeostasis (Ben-Othman et al. 2013b).  
The endocrine component of the pancreas is organized in small clusters of cells 
termed islets of Langerhans, first identified by the biologist Paul Langerhans in 1869. Each 
islet is a micro-organ containing hormone-producing cell types including alpha (α), beta (β), 
delta (δ), epsilon (ε) and PP cells, which produce and secrete glucagon, insulin, somatostatin, 
ghrelin and pancreatic polypeptide, respectively (Adrian 1978; Wierup et al. 2002; Heller et 
al. 2005; Collombat et al. 2006; Guney & Gannon 2009). Specifically, the hormones insulin 
(β-cells) and glucagon (α-cells) maintain glycaemic homeostasis (70-100mg/dl) by regulating 
the storage, metabolism and neogenesis of glucose.  
Insulin is secreted in response to a variety of stimuli, including parasympathetic 
signals as acetylcholine (Gilon & Henquin 2001), the incretin peptides glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), high blood glucose 
levels and glucagon (Figure 3) (Baggio & Drucker 2007). Insulin activates the cellular uptake 
of glucose, by inducing its storage in the muscle, liver or adipose tissues, thereby reducing the 
blood glucose levels. In the liver, glucose is converted in glycogen, a reaction catalysed by the 
enzyme glycogen synthase. Liver glycogen serves as the main repository of glucose (Agius 
2008).  
On the other hand, when sugar levels are low, α-cells counteract the effects of insulin 
by secreting glucagon that will induce the catabolism of glycogen in the liver, in a process 
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called glycogenolysis. Glucagon also stimulates the conversion of noncarbohydrate substrates 
into glucose (gluconeogenesis) Taken together, theses processes will result in an increase of 
circulating glucose (Ben-Othman et al. 2013b). 
 
Figure 3: Functional β-cells secrete insulin in response to increasing glucose levels. In glucose-stimulated 
insulin secretion (GSIS), glucose is transported into the cell through glucose transporters (for example Glut1 or 
Glut2), where it is phosphorylated by glucokinase (GCK). The following metabolic reactions increase ATP 
levels. Rising ATP levels trigger the closure of potassium channels (Sur1 and Kir6.2 subunits), causing 
membrane depolarization and the opening of calcium channels. The resulting increase in intracellular calcium 
levels stimulates the exocytosis of insulin-containing granules and consequently leads to an increase in insulin 
levels in neighbouring blood vessels. Human genetic studies of maturity onset diabetes of the young (MODY) 
patients have identified a number of mutations that trigger diabetes, including those in genes encoding 
transcription factors (illustrated in the nucleus) and components of the GSIS pathway indicated in the figure. 
Adapted from (Pagliuca & Melton 2013). 
 
 
1.2.2 Islet vasculature 
 
The typical view of the islet cellular architecture has been formed based on early 
observations on the mouse, where β-cells cluster preferentially at the core of the structure and 
alpha, delta and PP cells are peripherally arranged. However, there are differences between 
species both in islet cell composition and cytoarchitecture: in human and nonhuman primates, 
alpha-cells are scattered throughout the islet rather than concentrated in the periphery 
(Wieczorek et al. 1998; Ballian 2007). There is evidence that these architectural differences 
have functional implications, suggesting that there is a possible correlation between the 
Pancreas
Islet
Glucose Depolarization
Insulin
β-Cell
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pattern of distribution (clustered or scattered) and islet cell function. However, additional 
studies are needed to clarify this hypothesis (Ballian 2007). 
Islets are very vascularised, to ensure the efficient secretion of endocrine hormones 
into the bloodstream. A complex network of capillary vessels and connective tissue, critical to 
their high metabolic activity, surrounds adult islets. Thus, although islets compose 1-2% of 
the total mass of the pancreas, they receive almost 15% of the overall blood flow to the organ, 
using 25% of the pancreatic oxygen supply. Islet blood flow is regulated by extracellular 
signals, such as hormones and nutrients that reach the islet vasculature from other tissues via 
the bloodstream. Also, islet perfusion determines communication between endocrine and 
exocrine cells and between different types of endocrine cells within islets (Konstantinova & 
Lammert 2004; Ballian 2007). 
 
 
1.3 Pancreatic Specification 
 
 Pancreas formation is dependent on several successive prerequisites that need to be 
fulfilled. Sonic hedgehog (Shh) signaling mediates the gut endoderm patterning. Shh is highly 
expressed in the gut epithelium, but it is down-regulated in a Ptf1α(p48)/Pdx1 region that will 
latter become the pancreas at e8.0. Both Shh repression and activation of Ptf1α and Pdx1 are 
required events for pancreatic specification. The areas defined by expression of Pdx1 and 
repression of Shh will start to branch out dorsally and ventrally (Domínguez-Bendala 2009).  
 
 
1.3.1 Transcription factors involved in pancreatic differentiation 
 
Pdx1 
The pancreatic and duodenal homeobox 1 gene (Pdx1) is also known as insulin 
promoter factor 1 (Ipf1) or islet duodenum homeobox 1 (IDX1). It is expressed in islet β-cells, 
in the adult mouse, and its function is to bind and regulate the insulin promoter. During 
development, Pdx1 expression is restricted to the dorsal and ventral walls of the pancreatic 
buds (Ohlsson et al. 1993). Mice homozygous for a targeted mutation in the Pdx1 gene 
selectively lack the pancreas, demonstrating that Pdx1 is needed for the formation of the 
pancreas. Also, direct cell lineage tracing in the mouse pancreas demonstrated that Pdx1-
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expressing progenitors in the early embryo give rise to all pancreatic cells (Gu et al. 2003). 
Thus, Pdx1 stimulates insulin gene transcription. Taken together, these data suggest that Pdx1 
is needed not only for early development of the primitive gut but also for the maturation of 
the β-cell (Jonsson & Ahlgren 1995). 
 
 
Ptf1α (p48) 
 Ptf1α is the α-subunit of the pancreas-specific transcription factor 1 (Ptf1), a basic 
helix-loop-helix (bHLH) protein that was first described as a DNA-binding element that 
regulates the expression of α-amylase 2, elastase 2 and trypsin in the acinar pancreas (Cockell 
et al. 1989). This gene is key regulator of acinar tissue development, but also important for 
the initiation of pancreatic development (Krapp et al. 1998).  
 
 
HNF-6 (OC-1) 
 HNF-6 (hepatocyte nuclear factor), also known as Onecut-1 (OC-1), belong to the OC 
family of transcription factors (Lemaigre et al. 1996). During development, HNF-6 is 
expressed in the epithelial cells that are precursors of the exocrine and endocrine pancreatic 
cells. HNF-6 binds to and stimulates the Ngn3 gene promoter (Jacquemin et al. 2000). Thus, 
HNF-6 acts upstream of Pdx1, controlling its activity in the ventral and in the dorsal 
endoderm, highlighting its importance as a key regulator of pancreas development (Jacquemin 
et al. 2003). 
 
 
Hlxb9 
Human homeobox gene 9 (Hlxb9), also termed as HB9, its encoding protein (Harrison 
et al. 1994). Hlxb9 regulates gene expression early in development (e8) in the notochord and 
in pancreatic endoderm (dorsal and ventral) (Li et al. 1999). It is also expressed in fully 
differentiated β-cells. Hlxb9 expression precedes that of Pdx1, suggesting an active role in 
shaping the early events of pancreatic specification. Hlxb9 knockouts show agenesis of the 
dorsal pancreas, with abnormal development of the ventral lobe (Harrison et al. 1999; Li et al. 
1999). 
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1.3.2 Endocrine specification 
 
Ngn3 
 Neurogenin 3 (Ngn3) encodes a class B bHLH factor. Ngn3 induces the endocrine fate 
choice (Apelqvist et al. 1999), being a required factor for the development of all the endocrine 
cell lineages of the pancreas. Gain-of-function studies (Apelqvist et al. 1999), as well as 
lineage tracing experiments show that Ngn3 is a cell-autonomous determinant and true marker 
of endocrine progenitor cells (Gu et al. 2002; Gu et al. 2003). The pattern of adoption of 
endocrine cell fates seems to have a specific timeline, suggesting that Ngn3-positive cells 
adapt their responses to the changing signaling in the bud environment. Early Ngn3 
expression in pancreatic progenitor cells (e8.5-e9) results in their differentiation into 
glucagon-producing cells (Domínguez-Bendala 2009). In contrast, during the secondary 
transition, there is a second wave of Ngn3 expression, which activates the expression of other 
endocrine transcription factors, such as Neurod1, Pax4 and Nkx2.2 and the latter two will 
drive the differentiation into β-cells (Van Hoof et al. 2009). 
 
Isl1 
 Isl1 is a LIM homeodomain protein, a family of proteins with a DNA binding 
homeodomain and two LIM domains, (the LIM domains are 50–60 amino acids in size and 
share two charac- teristic zinc finger domains, which are separated by two amino acids) 
(Zheng & Zhao 2007). During development, Isl1 is required for the formation of the dorsal 
pancreatic mesenchyme. Also, Isl1 expression in pancreatic epithelial cells drives 
differentiation of islet cells and it is expressed upon maturation of endocrine cells (e9 for 
glucagon-positive cells, e10.5-11 for insulin-positive cells) (Adolphs et al. 1997). 
 
 
NeuroD/BETA2 
 BETA2, (beta-cell E-box transactivator 2, also known as NeuroD) is a cell-restricted 
bHLH, expressed in pancreatic β-cells, that was shown to be a component of the native 
insulin E-box-binding complex, which suggests that BETA2 is an important regulator of the 
insulin gene (Naya et al. 1995).  BETA2-deficient mice showed a dramatic reduction in the 
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number of β-cells and failed to develop well-organized, mature pancreatic islets, indicating 
that this transcription factor may be involved in the maintenance and proliferation of the islet 
cell types (Naya et al. 1997). Finally, Ngn3 was shown to be involved in the upstream 
regulation of BETA2 expression at an early stage of islet cell differentiation (Huang et al. 
2000). 
 
 
1.3.3 Islet cell sub-types: β-cell differentiation 
 
While all the cells of the endocrine pancreas are thought to arise from a common 
endodermal precursor, little is known about the extracellular signals that direct beta cell 
differentiation from Ngn3+ progenitors (Sussel et al. 1998). Here, a special emphasis will be 
done on the differentiation of endocrine β-cells, which are destroyed in T1DM, highlighting 
the role of the genes that act as master regulators in this transition.  
 
Nkx2.2 
 Nkx2.2 is a member of the mammalian NK-homeobox transcription factor family and 
its expression is essential for normal beta cell development (Sussel et al. 1998). Nkx2.2 is 
initially expressed at e9.5, upon formation of the dorsal pancreatic bud. However, during the 
secondary transition, when different exocrine and endocrine compartments can be identified, 
Nkx2.2 expression becomes limited to most of the endocrine cell types, being further 
restricted to α, β and PP cells of the mature islet. In the adult, expression of Nkx2.2 is 
preserved and is not detectable in the exocrine tissue (Sussel et al. 1998; Sander et al. 2000). 
 
Nkx6.1 
The transcription factor Nkx6.1 is another member of the NK-homeodomain family. In 
the pancreas, Nkx6.1 has an expression pattern similar to that of Nkx2.2, being first detected at 
e10.5 in the pancreatic epithelium. The major difference is that Nkx6.1 expression becomes 
restricted to β-cells. Homozygotic mutation of the Nkx6.1 gene in mice inhibits β-cell 
formation, which becomes evident during the secondary transition. Nkx2.2 expression was not 
affected, suggesting that this gene acts upstream of Nkx6.1. Double Nkx2.2/Nkx6.1 knockout 
mice experiments confirmed this hypothesis (Sander et al. 2000).  
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Pax4 
Paired box-containing gene 4 (Pax4) is a member of the paired domain family of transcription 
factors, a family that shares a highly conserved motif with DNA-binding activity, named 
“paired box”. Also, both Pax4 and Pax6 have a homeodomain (Walther et al. 1991; 
Dohrmann et al. 2000). Pax4-/- deficient mice do not generate neither insulin-producing β-cells 
nor δ-cells within the pancreas (Sosa-Pineda et al. 1997). There is also evidence that Pax4 
acts as a direct downstream target of Ngn3 (Heremans et al. 2002; Smith et al. 2003). 
 
Pax6 
Paired box-containing gene 6 (Pax6) is also a member of the paired domain family of 
transcription factors (Walther et al. 1991). Pax6 is known for being expressed in the CNS 
(Walther & Gruss 1991) and for its crucial role in eye development (Richardson et al. 1995). 
However, it is also expressed both in pancreas development and latter in alpha-, beta- or 
delta-cells in the adult pancreas (it is not expressed in the acinar tissue) (Sander et al. 1997; 
Dohrmann et al. 2000). Pax6-deficient mice show a dramatic reduction in all endocrine cells, 
with α-cells almost absent, suggesting that Pax6 is required for the formation of α-cells (St-
Onge et al. 1997). 
 
MafA and MafB 
MafA belongs to the Maf gene family of transcription factors containing a basic 
leucine zipper. This family has been associated with the regulation of cell differentiation in 
vertebrates (Ochi et al. 2004). MafA is expressed within the pancreas, preferentially in β-cells 
whereas MafB is expressed in α-cells. MafA has been identified as a transcription factor that 
binds to a promoter element of the insulin gene and is thought to regulate insulin transcription 
in response to serum glucose levels (Kataoka et al. 2002). MafA Knockout mice revealed 
glucose intolerance and developed diabetes, as well as diminished insulin transcription. 
Another observation was that MafA-deficient mice were unable to respond to glucose-
stimulated insulin secretion (GSIS), suggesting that MafA is a key regulator of GSIS (Zhang 
et al. 2005). 
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Figure 4: Essential expression patterns of transcription factors during beta-cell formation. At the top, arrows 
point to the developmental steps at which the indicated transcription factors have been shown to be 
indispensable in genetic knock-out studies of mice, irrespective of when these genes are expressed. At the 
bottom is a representation of the relative expression levels of different transcription factors throughout pancreatic 
development.  
 
 
 
1.4 Possible strategies to generate new pancreatic β-cells 
 
Insulin injections treat but do not cure T1DM (Best et al. 2008). Islet transplantation 
allows for insulin-independency in for a number of years. However, there are some obstacles 
underlying this approach since there are no enough donors to balance the demand, and it 
involves possible toxic imunossuppression (Halban 2004). To overcome this problem, the 
large scale in vitro production of β-cells for replacement therapy offers an aspiring solution.  
The strategies for in vitro beta cell production are: 1) step-wise derivation of insulin-
producing cells from embryonic stem cells, 2) In vitro β-cell expansion and redifferentiation, 
and 3) Reprogramming of a terminally differentiated cell type into insulin-producing cells. 
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1) Step-wise derivation of insulin-producing cells from embryonic stem cells 
 
Embryonic stem cells (ESCs) have not been differentiated yet into phenotypically 
normal β-cells. Current protocols try to mimic the normal differentiation pathways that take 
place during normal pancreatic development. However, the major challenge is to discover 
strategies for designing protocols that follow the normal development. D’Amour et al. were 
the first to develop an efficient in vitro protocol for early induction of ESCs to a foregut-like 
phenotype by the addition of Activin-A, followed later by induction to a more specific 
pancreatic phenotype (D’Amour et al. 2005; D’Amour et al. 2006). Still, further 
improvements are necessary for generating functional β-like cells. 
 
 
2) In vitro β-cell expansion and redifferentiation 
 
Another strategy for producing β-cells is the induction of in vitro replication of 
existing β-cells to provide abundant source of human insulin-producing cells. However, the 
major obstacle is that the expansion of isolated human islets in tissue cultures is very difficult, 
since the islets show partial or complete loss of function (Beattie et al. 2002). In another hand, 
a recent cell-lineage report showed that islet insulin-expressing cells maintain a renewal 
capacity for islet regeneration after injury (Dor et al. 2004). Ouziel-Yahalom et al. described 
culture conditions that allowed replication of dedifferentiated human islets in culture and later 
favored their redifferentiation using a number of factors known to allow β-cell differentiation 
and proliferation. Nevertheless, these new differentiated cells were not glucose-responsive 
(Ouziel-Yahalom et al. 2006). 
 
 
3) Reprogramming of a terminally differentiated cell type into insulin-producing cells 
 
An alternative strategy to differentiating β-cells in a stepwise approach from 
embryonic stem cells is the reprogramming of terminally differentiated cell types into β-cells. 
This method for direct reprogramming allowed the reprogramming of fibroblasts to generate 
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iPSCs, cardiomyocytes, or neurons (Takahashi et al. 2007; Ieda et al. 2010; Vierbuchen et al. 
2010). Due to this success, reprogramming other cell types into the β-cell phenotype could be 
of relevance in the regenerative medicine field. 
 One example of this reprogramming strategy was the demonstration of the direct 
reprogramming pancreatic exocrine tissue into the β-cell fate in vivo using a combination of 
three genes (Pdx1, Ngn3 and MafA), delivered by adenoviral vectors (Zhou et al. 2008). The 
new insulin-positive cells were detected after injection of the adenoviral mix into the pancreas 
of Rag1-/- mice (a strain used to decrease the immune response induced when using a viral 
delivery method) (Wang et al. 2007). These cells expanded for up to three months after 
injection, after the adenoviruses had been cleared from the recipients. Importantly, these cells 
also expressed key markers of β-cell phenotype, such as Nkx6.1, Glut2 and glucokinase and 
no longer expressed markers for the acinar function (Zhou et al. 2008). These induced cells 
showed to improve glycaemic control in diabetic mice, although diabetes was not completely 
reversed. One possible explanation for this observation could be that new insulin-positive 
cells did not cluster to form islets and β-cell communication is crucial for stimulation of 
glucose-mediated insulin secretion (Zhou et al. 2008). 
Although acinar cells had been reprogrammed into β-cell in vivo, there is still not 
known how to drive differentiation of mouse or human cell types into a β-cell in vitro. This 
might be explained by the insufficient knowledge about the in vitro culture conditions that are 
necessary for the preservation of β-cell identity and function (Pagliuca & Melton 2013).  
Another example of terminally differentiated cell reprogramming into β-cells was 
reported recently, this time using mouse endocrine α-cells. Mansouri et al. revealed that 
ectopic expression of Pax4 was sufficient to transdifferentiate α-cells into β-cells in vivo 
(Collombat et al. 2009), which correlates with the common developmental pathway of these 
cell types. Also, current studies reported that α-cells have bivalent chromatin signatures at 
genes that are active in β-cells. This report suggests that α-cells may have the inherent 
capacity to be reprogrammed into β-cells, since this β-cell genes have already the capacity to 
be active (Bramswig & Everett 2013). 
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1.5 Aim of this work 
Any progress in obtaining large number of transplantable insulin producing cells 
would be a major advance towards a cure for the disease.  
The goal of this work was to set up the required tools to transdifferentiate adult human 
cells to the beta cell phenotype by direct reprogramming mediated by forced expression of an 
optimized set of pancreas specific transcription factors. The underlying experimental rationale 
is that sequential or combinatorial ectopic expression of transcription factors can induce 
recipient cells to establish a beta cell regulatory state. 
 
1.6 Strategy  
1.6.1 Pancreas Specific Transcription Factors 
Differentiated adult somatic cells retain the capacity to be reprogrammed into other 
cell types (L. Baeyens et al 2009). This process presumably occurs because there is a change 
in the expression of key transcription factors - also called master switch genes - that alters the 
state of cell developmental commitment (Table 3). 
Ectopic expression of particular combinations of transcription factors can result in 
direct conversion of one cell type into another by altering the underlying regulatory state of 
the initial cell (Papp & Plath 2011). Therefore, the main goal was to create a library of 
transcription factors known to play key roles in normal pancreatic development in 
doxycycline inducible lentiviral vectors and to attempt to find a combination of factors 
capable of transdifferentiating human fibroblasts to the β-cell state.  
The strategy is to transduce an easily obtainable human cell type with the library and 
culture the cells in conditions known to favor beta cell phenotype maintenance.  
	   28	  
 
        Adapted from (Best et al. 2008). 
 
 
1.6.2 Lentiviral Delivery 
 
Conversion of somatic cells into a beta cell phenotype will be done by ectopic 
expression of the lineage-specific transcription factors using a Tet-ON Lentiviral Vector. The 
Tet-ON system allows the tight control of the gene expression. In this system, the gene 
expression is turned on when Tetracycline (Tc) or Doxycicline (Dox) is present in the culture 
media. In contrast, expression is turned off in the Tet-ON System by removing Dox from the 
media. The genes of interest are expressed under control of Tetracycline Responsive Element 
(TRE). In the presence of Dox, the reverse tetracycicline transactivator (rtTA) binds the TRE 
element and thereby activates transcription of the genes (Figure 5). 
 
 
Cell type Transcription factor Function 
Table 3 - Summary of transcriptional regulators involved in the formation of the early gut tube through to the specification of islet cell type 
Reference 
Gut tube GATA4 Foregut morphogenesis; differentiation of both exocrine and endocrine 
lineage; transactivates glucagon gene 
Bossard and Zaret, 2000; Kertola et al., 2004; 
and Ritz-Laser et al., 2005
FOXA2 Homozygous knockout lethal in mice due to lack of endoderm and 
notochord; required for alpha-cell lineage
Monaghan et al., 1993; and Lee et al.,2005
Pancreas specification PDX1 Essential for pancreatic development; differentiation of alpha- and 
beta-cells; transactivator of insulin gene 
Jonsson et al., 1994; Offield et al., 1996; 
and Hui and Perfetti, 2002
SOX9 Expressed in all pancreatic progenitors cells; islet organization;
restricted to duct cells later in development
Piper et al., 2002; Akiyama Ddagger et al., 
2005; and Seymour et al., 2007
SOX4 Broadly expressed in pancreatic buds with subsequent restriction 
to islets 
Wilson et al., 2005
HLXB9 Expressed in all pancreatic progenitors with restriction to 
beta-cells during differentiation
Harrison et al., 1999; and 
Li et al., 1999
PBX1 Expressed in pre-pancreatic epithelium; required for both exocrine
and endocrine differentiation
Dutta et al., 2001; and 
Kim et al., 2002
PTF1a Expressed in all pancreatic progenitors; essential for exocrine
development
Krapp et al., 1996; and 
Kawaguchi et al., 2002
HNF1β Expressed in early endoderm; regulator of HNF6 expression Barbacci et al., 1999; and 
Poll et al., 2006
HNF6 Pancreatic precursor cell specification; regulates PDX1 and NGN3
expression; islet and duct cell formation 
Jacquemin et al., 2000; Jacquemin et al., 
2003; and Poll et al., 2006
Endocrine specification NGN3 Differentiation of endocrine lineage Apelqvist et al., 1999; Jensen et al., 2000; 
Schwitzgebel et al., 2000; and Sugiyama et 
al., 2007
ISL1 Differentiation of all islet cell types Apelqvist et al., 1997;
NEUROD1 Differentiation of all islet cell types; islet organization; transactivates 
insulin gene 
Naya et al., 1997;
Islet cell subtypes HNF4α Transactivation of HNF1α and insulin gene Gragnoli et al., 1997; and Bartoov-Shifman 
et al., 2002
HNF1α Transactivation of PDX1 and insulin gene Emens et al., 1992; and Guerrish et al., 
2001
PAX6 Differentiation of all islet cell types; transactivates glucogon gene Sander et al., 1997; and St-Onge et al., 
1997
PAX4 Formation of alpha- and beta-cells Sosa-Pineda et al., 1997; and Smith et al., 
1999
NKX2.2 Transactivation of NKX6.1 and insulin genes in beta-cells 
progenitors 
Sussel et al., 1998
NKX6.1 Differentiation of beta-cells Sander et al., 2000
MAFA Transactivates insulin gene Kataoka et al., 2002
GATA6 Differentiation of endocrine lineage; expressed in beta cells Ketola et al., 2004
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Figure 5: Representation of the Tet-ON Lentiviral Vector (9.6Kb). In grey, Woodchuck hepatitis 
responsive element; AmpR, ampicillin resistance gene; TRE, tetracycline responsive element; CmR, 
chloramphenicol resistance gene; rtTA2, reverse tetracycline transactivator.  
 
 
 
1.6.3 The reporter vector 
 
Cell identity will be identified using a lentiviral reporter vector expressing GFP and 
RFP under the control of the Insulin and Pdx1 promoters respectively (Figure 6). Cells 
turning on the reporter could be isolated by FACS and analyzed by PCR to identify the 
identity of the transcription factors inserted in their genome. Stability of the phenotypic 
transformation could be assessed by testing reporter activity in conditions that repress the 
expression of the pancreatic transcription from the lentiviral vectors (Figure 7). 
 
 
 
 
 
Figure 6: Schematic representation of the lentiviral dual-reporter system containing the Pdx1 and insulin 
promoters driving expression of a monomeric red fluorescent protein and enhanced green fluorescent protein 
(Szabat et al. 2009). Pdx1 is a master regulator of pancreatic development, islet survival, and beta cell function. 
Insulin is the main functional product of the cell type we wish to obtain by transdifferentiation. 
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Figure 7: Schematic representation of the strategy used for direct reprogramming into beta cell phenotype 
mediated by expression of pancreatic transcription factors. Ectopic co-expression of the reporter vector and the 
reprogramming factors in an initial cell type 
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2. METHODS AND RESULTS 
 
The first and basic task of this thesis was to clone a library of pancreas specific 
transcription factors into a doxycicline inducible lentiviral vector. Cloning the transcription 
factors (TF) into such an inducible lentiviral vector was considered crucial, as induction of 
expression of the TF would be needed for triggering transdifferentiation. Nevertheless, 
repression of expression would be important to determine if the phenotypic conversion would 
be stable in the absence of exogenous TF expression. Therefore we attempted several 
different cloning strategies. 
 
 
2.1 The Gateway Cloning System 	  
The Gateway System is a cloning method that provides an efficient way to clone a 
gene of interest into a vector of choice, based on the site-specific recombination properties of 
the bacteriophage lambda. The system is based on recombination between DNA sequences 
present in bacterial genomes (attB), and in the phage genome (attP). When a phage infects a 
bacterium, there is a recombination reaction between the attB and the attP sequences, which 
will result in integration of the phage DNA into the bacterial genome (Hartley 2000). 
The product of recombination between an attB site and an attP (ie, a BP recombination 
reaction) site produces a new recombination site called attL. In turn, an attL sequence can 
recombine with another sequence named attR (ie, a LR recombination reaction) to restore an 
attB site. 
These recombination reactions are the basis of the Gateway Cloning System, a 
commercially available system designed to facilitate the cloning of genes of interest and their 
subsequent transfer to more complex vectors for a number of purposes. In a first step, the 
gene of interest is amplified by PCR with primers containing the attB1 and attB2 sites in the 
forward and reverse gene specific primers respectively. This PCR fragment is introduced into 
pDonor, a plasmid containing a ccdB toxic gene (flanked by attP1 and attP2) in a 
recombination reaction catalyzed by the enzyme BP clonase, resulting in the exchange of the 
gene of interest for the ccdB cassette, generating a new plasmid called pEntry (Figure 8). 
The reaction mixture is transformed into ccdB sensitive bacteria, ensuring that only 
recombinant clones (clones with a pDonor backbone carrying the gene of interest flanked by 
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attL1 and attL2 sites) are obtained. These can be analyzed by restriction digest analysis and 
sequencing to confirm their identity and integrity. 
 
 
 
 
Figure 8: Schematic representation of the BP recombination reaction in order to generate the desired 
Entry Clone. A) PCR amplification using primers that have the attB1 and attB2 sites flanking the gene of 
interest. B) The Donor Vector contains a ccdB toxic gene flanked by attP1 and attP2, and a kanamycin resistance 
gene for positive selection. C) After the BP recombination reaction of the gene of interest into the Donor vector, 
the ligation reaction is transformed into ccdB sensitive bacteria and selected with kanamycin. The resulting 
clones will have the pEntry clone, which now contains the gene of interest flanked by attL1 and attL2 sites. 
Adapted from Invitrogen. 
 
 
	  
 
Figure 9: Schematic representation of the LR recombination reaction in order to clone Entry Clone into 
Destination Vector. A) Entry clone with the gene of interest flanked by attL1 and attL2 sites. B) Destination 
vector containing a ccdB gene and chloramphenicol resistance gene flanked by attR1 and attR2 sites. C) After 
LR recombination reaction of these two vectors, the ligation reaction is transformed into ccdB sensitive bacteria 
and selected for ampicillin resistance. The final plasmid (named expression clone) will now have attB1 and 
attB2 sites that result from recombination of attL and attR sites. Adapted from Invitrogen. 
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Once the Entry clones are obtained, the DNA of interest can be cloned into a 
destination vector in a recombination reaction catalyzed by the enzyme LR Clonase II, 
resulting in the formation of sticky ends in the attL sequences that will consequently match 
with the attR sticky ends in the destination vector. This will result in the exchange of the gene 
of interest for the ccdB gene producing a new plasmid, termed Expression clone (Figure 9). 
The expression clone now contains the gene of interest and a resultant recombinant att 
sequence, named attB site and is now ready to transfect into E.Coli following selection for the 
recombinant clones. 
This site-specific recombination cloning system allows the efficient transfer of gene-
coding sequences from one vector (Entry clone) to any expression clone modified with the 
necessary recombination sites flanking the insertion site for the gene-coding sequences 
(Destination vector). 
 
2.2 Construction of the Gateway Destination Vector 
 
We obtained a number of pancreas specific transcription factors from a library of 
transcription factors that had been cloned into pEntry vectors. Of note, this library had been 
designed for the creation of fusion proteins and therefore the open reading frames lack the 
stop codons. We chose to clone these factors into an appropriate destination vector and 
planned to add stop codons at a later stage.  
Our goal was to clone a collection of pancreatic specific transcription factors into a 
doxycycline regulatable lentiviral vector. Therefore, we required the appropriate gateway 
destination vector. 
In order to generate the final destination vector, the lentiviral vector Lenti-Tet-ON-
ires-GFP was used (Figure 10).  
 
 
Figure 10: Representation of the original vector Lenti-Tet-ON-IRES-GFP.  
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The original plasmid was digested with restriction enzymes (MluI and EcoRV) and its 
backbone was gel purified using QIAquick gel extration Kit (Qiagen). Because MluI cut 
leaves a 5´-overhang, the original backbone was incubated with dNTPs and Klenow fragment 
for 15 minutes at 65C, following incubations at 25ºC for 15 minutes and 75ºC for 20 minutes. 
This procedure resulted in the fill-in of the 5'-overhang and the generation of blunt DNA 
ends. The vector backbone was then treated with alkaline phosphatase to remove the 5’ 
phosphates in order to minimize re-ligation of the vector.  The plasmid containing the 
destination cassette was digested with EcoRV and gel purified using QIAquick gel extration 
Kit (Qiagen). After that, the destination cassette (contained the attR1 and attR2 sites and both 
a ccdB gene and a chloramphenicol resistance marker) was ligated into the vector using a T4 
DNA ligase. The ligation reaction was transformed into electrocompetent bacteria resistant to 
ccdB and selected for Ampicilin.  
The resultant plasmid (from now on termed destination vector – also see Figure 5) was 
confirmed by restriction and sequencing (Figure 11). 
 
 
 
Figure 11: Restriction pattern of  Lenti-Tet-ON Destination Vector analysed by agarose electrophoresis. The 
expected bands are: in lane 1) 7.4kb, 1.34kb, o.7kb and 0.25kb; in lane 2) 4.9kb, 3.34kb, 0.58kb, 0.55 kb and 0.3 
kb; in lane 3) 3.39kb, 2.65kb, 2.52kb and 0.77kb. 
 
 
The genes of interest were cloned into the destination vector using Gateway 
technology, as described before. The genes were obtained from a commercial library already 
cloned into pEntry vectors and lacking stop codons as explained above. The transcription 
1 2 3L
L - 1kb DNA ladder 
1 - Digested with BamHI
2 - Digested with HindIII 
3 - Digested with PvuII
Lenti-Tet-ON Destination Vector
1000
3000
6000
bp
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factors were transferred into the destination vectors by a LR recombination reaction between 
the entry clone and the converted gateway destination vector. 
 
The first library of genes cloned into gateway destination vector (Library 1) was 
already cloned in pEntry vector by the time in which the cloning has started.  
 
. 
Table 4: Library 1 - Genes cloned in pEntry vector 
pE-ISL1 pE-UBA2 
pE-HADHB pE-ES1 
pE-NeuroD pE-IL1 
pE-MafA pE-COX2 
pE-CKD4 pE-M4T1 
pE-PAX6  
 
 
The identity of clones in pEntry was confirmed by restriction and sequencing. All the 
clones showed the right restriction pattern (data not shown). For the clones which identity was 
confirmed by sequencing, a LR recombination reaction was performed in order to clone the 
genes of interest into the destination vector (Figure 12), followed by new restriction and 
sequencing to confirm the final clones that were obtained (Figure 13). 
Note that the sequences of transcription factors belonging to Library 1 did not 
contained the stop codon, since these plasmids were first generated for the construction of 
recombinant proteins. Nevertheless, since the goal of this work was to test the effect of 
ectopic expression of several transcription factors in order to reprogram somatic cells into the 
beta cell phenotype, the stop codons would need to be added be added to the sequences at a 
later step (see Site-directed mutagenesis protocol below). 
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Figure 12: Schematic representation of the generation of the final expression clones using the 
Gateway System for clones in Library1. A) Library1 containing several transcription factors cloned 
into pEntry vector. B) Clones which identity was confirmed by sequencing; LR recombination 
reaction into destination vector. C) Clones successfully cloned into destination vector were confirmed 
by restriction enzyme digestion and sequencing. D) Stop codon was added into the sequences of genes 
cloned in C) using Site-Directed Mutagenesis Kit (Nzytech). The success and failure of the different 
strategies is here represented as “YES” or “NO”, respectively.  
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Figure 13: Restriction pattern of Lenti-Tet-ON-IL1 (lanes 2 to 5) and Lenti-Tet-ON-MAFA (lanes 6 and 7) 
analysed by agarose electrophoresis. L, 1kb letter; #1, #2, #3 and #4 refer to different clones that were subjected 
to restriction. The expected bands are: For Lenti-Tet-ON-IL1: 6kb, 0.8kb, 0.76kb, 0.68kb and 0.6kb; Lenti-Tet-
ON-MAFA: Cut with EcoRI: 6kb, 0.76kb, 0.68kb, 0.6kb, 0.35kb and 0.3kb; Cut with BamHI: 7kb, 1.1kb and 
0.27kb. 
 
 
Despite multiple attempts, we were unable to clone some of our candidate 
transcription factors into our destination vector by LR recombination. This situation is not 
unheard of when using the gateway system to clone inserts into complex constructs such as 
the LentiTETON destination vectors. Apparently, the system is dependent on the nature and 
sequence of the inserts being cloned and to obtain spuriously recombined and incorrect clones 
is sometimes known to occur. 
 
In order to reconstruct the missing stop codons in the final expression clones we 
subjected them to Site-directed Mutagenesis Kit (Nzytech). 
The Site-directed Mutagenesis Kit is a simple procedure designed to make 
modifications in a vector of choice, such as point mutations, and insertions or deletions of 
single or multiple amino acids (Figure 14). In this specific situation, the system was used for 
addition of the stop codons missing in the gene sequences of Library 1. Therefore, two 
synthetic oligonucleotide primers containing the mutation (in this case the stop codon) were 
designed, each one annealing to the same sequence, on opposite strands of the vector. PCR 
1000
3000
6000
bp
#1 #2 #3L #4 #3 #3
EcoRI EcoRI BamHI
L-Tet-ON IL1 L-Tet-ON MAFA
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amplification of the plasmid using these primers will generate a mutated plasmid containing a 
nick at the end of each circular strand. 
 
 
Figure 14: Schematic representation of the Site-directed mutagenesis method. Adapted from 
http://www.stratagene.com/manuals/200516.pdf.  
 
 
After that, the PCR product is digested with DpnI, which is an endonuclease specific 
for methylated DNA. DpnI is used to digest the parental DNA template and select for 
plasmids containing the desired mutation (the synthetic DNA is not methylated and therefore 
resists to DpnI digestion; DNA isolated from almost E.coli strains is dam methylated and 
consequently vulnerable to digestion with DpnI). 
The plasmid is finally transformed into competent cells and the latter will repair the 
nicks in the mutated vector.  
 
At the completion of this thesis, the Lenti-Tet-ON-NeuroD1 construct has been 
partially modified to reconstruct the stop codon (one base of the stop codon is still missing 
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and will require another round of mutagenesis) and the other three constructs (ISL1, MAFA 
and IL1) are awaiting repair. 
In summary, this cloning approach was not as efficient as hoped for. 
 
 
2.3 Cloning With Vaccinia Virus DNA polymerase using In-Fusion Kit (Clonetech) 
 
In order to clone the genes of interest into the lentiviral vector L-TET-ON, another 
strategy was adopted, which consisted in cloning the DNA of interest into the vector of choice 
by means of a recombineering technology based in recombination of virus in vivo. 
 This technology uses Vaccinia Virus DNA polymerase (VVpol), a polymerase that 
encodes a 3’- to 5’-proofreading exonuclease that is able to degrade the ends of the duplex 
DNA and therefore expose single-stranded DNA tails. As a result, complementary single-
stranded DNA tails can recombine giving rise to stable recombinant molecules. For this 
reason, VVpol can be used for directional cloning of PCR products (Figure 15).  
The target vector is linearized using restriction enzymes and the DNA of interest can be 
amplified by PCR using forward and reverse primers that contain a sequence of 16-18bp that 
is homologous to the two ends of the linearized vector. These products are then coincubated 
with VVpol, which will degrade the ends of the DNAs (through its 3’- to 5’ exonuclease 
activity) and expose the areas of complementary sequence. The single-stranded DNAs can 
anneal spontaneously since they share complementary sequences (this reaction is enhanced by 
adding vaccinia virus single-strand DNA binding protein – or I3 protein) and will form non-
covalently linked joint molecules. After transformation into E. coli, the E. coli DNA repair 
systems convert these molecules into stable recombinants. Because this cloning method can 
be used with any combination of homologous ends, it is a very useful system for directional 
cloning of PCR products into a target vector. 
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Figure 15: Principles of the cloning method using Vaccinia Virus DNA polymerase (VVpol). A) Digestion of the 
target vector with restriction enzymes and amplification of the gene of interest using primers that contain the 
sequences homologous to the vector ends. B) Co-incubation of both the linearized vector and the PCR product 
with VVpol. The 3’- to 5’ exonuclease activity of VVpol degrades and exposes the complementary sequences of 
the DNAs (see yellow boxes). C) Single-strand annealing of the complementary ends (this reaction is catalysed 
by I3 proein) and generation of joint molecules, that can contain a mix of gaps, nicks or extra nucleotides,  as a 
result of the variation in the coverage of exonuclease attack (white arrows). D) These joint molecules can then be 
transfected into E. coli and its repairing system will convert the joint molecules into stable recombinants. 
Adapted from (Irwin et al. 2012). 
 
 
A number of commercially purchased clones from our candidate list, as well as genes 
from library 1 that were not successfully cloned by gateway technology were amplified by 
PCR, cloned into pBluntZero using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen) and 
confirmed by sequencing and subjected to In-fusion cloning. Of note, in amplifying the 
transcription factors, MluI and EcoRV restriction sites were created upstream and 
downstream of the transcription factors open reading frames. Our rationale was that 
amplifying the transcription factors (TFs) open reading frames would further allow the 
cloning of the TFs into the lentiviral vector Lenti-Tet-ON using two alternative strategies: a) 
In-phusion cloning and b) Directional cloning using MluI and EcoRV restriction sites.  
 
This commercially available technique (Zero Blunt TOPO PCR Cloning Kit) is a rapid 
and simple cloning strategy used for the direct insertion of blunt-end PCR products into a 
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plasmid vector. It is a cloning technique based in the Topoisomerase I from Vaccinia virus, a 
virus-encoded eukaryotic type I topoisomerase that has the ability to cleave and rejoin DNA 
strands with high specificity (Shuman 1991). The Topoisomerase I binds to duplex DNA in 
specific sequences (5’-CCCTT) cleaving the phosphodiester backbone after 5’-CCCTT in one 
strand. In the cleavage reaction, the energy is conserved by the formation of a covalent bond 
between the 3’ phosphate of the cleaved strand and the tyrosyl residue of topoisomerase (Tyr-
274). The enzyme has the ability to religate to a heterologous acceptor DNA, creating a 
recombinant molecule (Shuman 1994).All the resulting vectors cloned using this strategy 
were restriction digested with enzymes and sequenced to confirm the identity of the 
pBluntZero plasmids containing the target genes.  
The library of genes successfully clone in pBluntZero were then used for two different 
cloning strategies: 1) T4 DNA ligase cloning strategy and 2) In-fusion Cloning.  
In the T4 DNA ligase cloning strategy, both the initial vector (L-Tet-ON-IRES-GFP) 
and the genes cloned into pBluntZero were digested with MluI and EcoRV, and gel purified 
using QIAquick gel extration Kit (Qiagen).  
Aftter gel purification, each gene of interest was introduced into the L-Tet-ON vector in 
a ligation reaction with T4 DNA Ligase. The ligation reactions were then transformed into 
DH5α electrocompetent bacteria and the resulting plasmids were digested with restriction 
enzymes and sequenced to confirm their identity. 
 
In the In-Fusion cloning approach, the initial vector was digested with MluI and 
EcoRV, to generate the target linearized backbone following gel purification (QIAquick gel 
extration Kit, Qiagen). The genes of interest (that were cloned into pBluntZero) were 
amplified using primers containing the sequence homologous to the two ends of the linearized 
vector and gel purified (QIAquick gel extration Kit, Qiagen). Co-incubation with VVpol and 
transfection into E.coli was performed as described before. The identity of the resulting 
clones was confirmed by restriction enzyme digestion followed by sequencing (Figure 16). 
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Figure 16: Schematic representation of the method used for generation of the final expression clones using the 
In-fusion technology or the T4 DNA Ligase strategy. A) Library1 containing several transcription factors cloned 
A	  
B	  
C	  
D	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into pEntry vector. B) Clones which identity was confirmed by sequencing; Amplification by PCR of the genes 
in Library 1 using primers containing each stop codon and MluI and EcoRV restriction sites. C) Clones 
successfully cloned into pBluntZero were confirmed by restriction enzyme digestion and sequencing. D) Two 
different strategies were used to clone the candidate genes into L-Tet-ON vector: the In-Fusion technology and 
the T4 DNA ligase. The resulting clones were restriction digested and sequenced to confirm their identities. The 
success and failure of the different strategies is here represented as “YES” or “NO”, respectively.  
 
 
 
Other genes showed to code for proteins that drive pancreas formation. For this reason, 
a second library of candidate genes was created (named Library 2). This library contains 
sequence-validated full-length protein-coding (FL-CDS) human cDNAs acquired from the 
Mammalian Gene Collection (Invitrogen), each one containing a start and a stop codon.  
 
Table 5: Library 2 -  cDNAs from the Mammalian Gene Collection 
GATA4 MSI2 
HHEX NKX6.1 
HNF1B PAX4 
FOXA2 PROX1 
HNF4A SOX9 
HNF6 TFCP2L1 
HOPX  
 
 The cDNAs clones were isolated from E.coli and analyzed by restriction followed by 
PCR amplification with flanking primers containing MluI and EcoRV restriction sites. The 
resulting PCR products were cloned into pBluntZero plasmid, as explained before. The 
identity of the clones was confirmed by restriction and sequencing. The cDNAs were 
introduced into the L-Tet-ON vector by the In-Fusion Cloning Kit (Clonetech), as mentioned 
before (Figure 17). 
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Figure 17: schematic representation showing the construction of the expression clones using the In-Fusion 
system. A) Library 2: cDNAs acquired from the Mammalian Gene Collection (Invitrogen) amplified by PCR 
using a forward and reverse primers containing an MluI and EcoRV restriction sites, respectively. B) PCR 
products were successfully cloned into pBluntZero vector and their identity and integrity was confirmed by 
restriction and sequencing. C) cDNAs were posteriorly cloned into L-Tet-ON vector by In-fusion strategy. The 
resulting clones were restriction digested and sequenced to confirm their identities. The success and failure of 
the different strategies is here represented as “YES” or “NO”, respectively.  
 
A	  
B	  
C	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A third strategy was used in order to isolate transcription factors thought to play a role 
in adult human islets. Since we had access to total mRNA from adult human islets, total 
mRNA was amplified by RT-PCR with attB flanked primers for a list of several candidate 
cDNAs that codify for these transcription factors (Table 6). 
The candidate cDNAs that were amplified with success were cloned into pDonor 
using the Gateway cloning system, as explained before. pDonor is a plasmid containing a 
ccdB toxic gene (flanked by attP1 and attP2). The recombination reaction was catalyzed by 
the enzyme BP clonase, resulting in the exchange of the gene of interest for the ccdB cassette, 
generating a new plasmid called pEntry. 
The resultant pEntry vectors were digested with restriction enzymes and sequenced to 
confirm their identity and integrity followed by cloning into the destination vector, also using 
gateway cloning strategy, as mentioned above (Figure 18). 
 
 
Table 6: Library 3 -  Candidate genes thought to play a role in  
human islets that were amplified by PCR 
CyclinD2 PBX1 
GATA4 PTF1a 
HNF3B SOX4 
HNF6 GATA6 
HOPX HDAC9 
NKX2.2 PROX1 
NKX6.1 SOX9 
TERT  
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Figure 18: schematic representation showing the construction of expression clones by the gateway system. A) 
Candidate cDNAs from total mRNA from adult human islets were amplified by RT-PCR with attB flanked 
primers for a list these several candidate cDNAs. B) PCR products that were successfully cloned into 
pDONR221 vector and which identity and integrity was confirmed by restriction and sequencing. C) cDNAs 
were posteriorly cloned into L-Tet-ON vector by gateway cloning system. The resulting clones were sequenced 
to confirm their identities. The success and failure of the different strategies is here represented as “YES” or 
“NO”, respectively.  
 
A	   B	  
C	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Finally, because only three cDNAs were amplified using human islets total mRNA, 
the last strategy used was to isolate putative transcription factors thought to play a role in 
human islets by amplification of more cDNAs from 293T total mRNA. To achieve this, total 
mRNA was amplified by RT-PCR with attB flanked primers for the same list of several 
candidate cDNAs (Table 6). PBX1 was successfully amplified by RT-PCR, and further 
cloned into pDonor vector using the Gateway cloning system, creating a pEntry vector. 
Although PBX1 had been cloned into pDonor, the sequencing results revealed that the actual 
sequence belonged to PBX2. Therefore, the cloning of this cDNA into the destination vector 
was not continued (Figure 19). 
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Figure 19: Strategy for the production of expression clones using the gateway system. A) Candidate cDNAs 
from 293T total mRNA were amplified by RT-PCR with attB flanked primers for a list these several candidate 
cDNAs. B) PCR products that were successfully cloned into pDONR221 vector. C) The sequencin results 
showed that pE-PBX1 was actually the wrong clone, and therefore this method was discontinued. The success 
and failure of the different strategies is here represented as “YES” or “NO”, respectively.  
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2.4 Virus Production Protocol 
 
The following protocol was used for the production of Lenti-tet-ON-Ngn3, Lenti-tet-
ON-Pax6, Lenti-Tet-ON-Pdx1, Lenti-Tet-ON-MafA. A lentiviral vector hPGK-GFP was used 
as a positive control. 
- Seed 4x106 293T cells in a 10cm plate; when cells reach 90% confluency proceed 
to transfection; 
 
Transfection procedure: 
-  10 cm plate 
Vector plasmid 10.0 µg 
PMDL 6.5 µg 
Rev 2.5 µg 
VSV-G 3.5 µg 
NaCl 150mM 890 µL 
PEI (polyethylenimine) 90 µL 
Total volume of 
transfection mix 1 mL 
 
- For DNA/PEI complex formation, the reaction must be carried out in an isotonic 
solution of NaCl (150mM); 
- The final volume of the reaction must be 1/10 of the volume in which cells were 
grown (otherwise the complex will precipitate);  
- Mix DNA into appropriate volume of NaCl 150mM; 
- Add PEI in a 4:1 ratio (4 µg of PEI per 1 µg of DNA); 
- Mix well (vortex immediately); 
- Leave at room temperature for 5 to 10 minutes; 
- Add homogeneously the solution (dropwise) that contains the DNA/PEI complex 
into the plate and swirl; 
- Incubate at 37ºC for six hours; Change the medium 6 hours after transfection for 
7.5 mL of Dulbecco's Modified Eagle Medium (Invitrogen) supplemented with 
10% FBS (Invitrogen), 1% PenStrep (Invitrogen) and 1% Glutamax (Invitrogen); 
- Incubate cells at 32ºC; 
- Collect the medium at 48 hours after transfection; Add 7.5mL of fresh medium to 
the plate and incubate cells at 32ºC; 
- Filter the medium through a 0.45 µm filter; 
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- Aliquot in 1.5mL tubes and proceed to storage at -20ºC for short term use or at -
80ºC for long term storage; 
- Collect the medium 24 hours later; Add 7.5mL of fresh medium and incubate cells 
at 32ºC; 
- Filter the medium as mentioned before, aliquot in 1.5mL tubes and proceed to 
storage at -20ºC for short term use or at -80ºC for long term storage; 
- Collect the medium 24 hours later; 
- Filter the medium as mentioned before, aliquot in 1.5mL tubes and proceed to 
storage at -20ºC for short term use or at -80ºC for long term storage. 
 
For the production of pTiger-Pdx1mRFP-Ins1eGFP, the following protocol was used. The 
lentivirus pTigerCMVeGFP and pTigerCMVmRFP were used as positive controls. 
 
- Seed 293T cells (4x106 cells per plate) in a 10cm plate; when cells reach 90% 
confluency proceed to transfection; 
 
Transfection procedure: 
-  10 cm plate 
Vector plasmid 9.0 µg 
pCPREnv 15.0 µg 
pCI-VSVG 18.0 µg 
NaCl 150mM 890 µL 
PEI (polyethylenimine) 90 µL 
Total volume of 
transfection mix 1 mL 
 
- For DNA/PEI complex formation, the reaction must be carried out in an isotonic 
solution of NaCl (150mM); 
- The final volume of the reaction should be 1/10 of the volume in which cells were 
grown (otherwise the complex would precipitate);  
- Mix the DNA into an appropriate volume of NaCl 150mM; 
- Add PEI in a 4:1 ratio (4 µg of PEI per 1 µg of DNA) and vortex; 
-  Leave at room temperature for 5 to 10 minutes; 
- Add homogeneously the solution (dropwise) that contains the DNA/PEI complex 
into the plate and swirl; 
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- Incubate at 37ºC for sixteen hours; Change the medium sixteen hours after 
transfection for 7.5 mL of Dulbecco's Modified Eagle Medium (Invitrogen) 
supplemented with 10% FBS (Invitrogen), 1% PenStrep (Invitrogen) and 1% 
Glutamax (Invitrogen); 
- Incubate cells at 32ºC; 
- Collect the medium at 48 hours after transfection; Add 7.5mL of fresh medium to 
the plate and incubate cells at 32ºC; 
- Filter the medium through a 0.45 µm filtre; 
- Aliquot in 1.5mL tubes and proceed to storage at -20ºC for short term use or at -
80ºC for long term storage; 
- Collect the medium 24 hours later; Add 7.5mL of fresh medium and incubate cells 
at 32ºC; 
- Filter the medium as mentioned before, aliquot in 1.5mL tubes and proceed to 
storage at -20ºC for short term use or at -80ºC for long term storage; 
- Collect the medium 24 hours later; 
- Filter the medium as mentioned before, aliquot in 1.5mL tubes and proceed to 
storage at -20ºC for short term use or at -80ºC for long term storage. 
 
 2.5 Biological Titre  
 
1) For the biological titre of the lentivirus Lenti-Tet-ON (MafA, Pdx1, Pax6 and Ngn3), 
the lentivirus Lenti-hPGK-GFP was used. 
2) For the biological titre of the reporter pTiger-Pdx1mRFP-Ins1eGFP, the lentivirus 
pTigerCMVeGFP was used. 
 
Titration procedure: 
-  Seed 293T cells (1x105 per well) in a 24 well plate 
- Make ten-fold serial dilutions of the viral particles in PBS;  
- The best dilution should have 10-30% GFP positive cells. 
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Serial dilutions: 
1) Undiluted (100 µL of viral particles) 
2) 1:10 dilution (10 µL of viral particles in 90 µL of PBS) 
3) 1:100 dilution (10 µL of 1:10 dilution in 90 µL of PBS) 
4) 1:1000 dilution (10 µL of 1:100 dilution in 90 µL of PBS) 
- Use 10 µL of each dilution to transduce 293T cells in 24 wells in 500 µL final 
volume. 
- Incubate cells at 37ºC and 48 hours later analyse by flow cytometry; 
- Calculate the transducing units per microliter (TU/µL) according to: 
 
TU/ µL = (P x N / 100 x V) x D, 
Where: 
P = % GFP positive cells 
N = number of cells seeded per well 
V = volume of supernatant  
D = dilution:   undiluted =1 
1:10 dilution =10 
1:100 = 100 
1:1000 = 1000 
After flow cytometry analysis, the titration results were: 
• TU/ µL (Lenti-Tet-ON vectors) = 3000 units/µL 
• TU/ µL (pTiger-Pdx1mRFP-Ins1eGFP) = 190.6 units/ µL 
 
 
2.6 Transdifferentiation Experiment 
For the transdifferentiation experiment, the following protocol was followed. 
- Seed 5x104  human Dermal Fibroblasts (Invitrogen) per well, in two 6-well cluster 
- Culture cells in DMEM (Invitrogen) medium supplemented with 10% FBS 
(Invitrogen), 1% PenStrep (Invitrogen) and 1% glutamine (Invitrogen); 
-  Add doxycycline to the medium in just one of the clusters; 
-  Calculate the multiplicity of infection (MOI) for both the Lenti-Tet-ON vectors 
and the pTiger-Pdx1mRFP-Ins1eGFP. 
 
 
	   53	  
Transduction procedure: 
1) All wells without Doxycycline 
Well#1: 
5x104 cells 
Negative control (no virus) 
 
 
Well#2: 
5x104 cells 
pTiger-Pdx1mRFP-Ins1eGFP 
MOI of 2 
Well#3: 
5x104 cells 
Positive control 
pTigerCMVeGFP 
MOI of 2 
Well#4: 
5x104 cells 
pTiger-Pdx1mRFP-Ins1eGFP 
L-Tet-ON-MafA 
L-Tet-ON-Pdx1 
L-Tet-ON-Pax6 
L-Tet-ON-Ngn3 
 
MOI of 2 
Well#5: 
5x104 cells 
pTiger-Pdx1mRFP-Ins1eGFP 
L-Tet-ON-MafA 
L-Tet-ON-Pdx1 
L-Tet-ON-Pax6 
L-Tet-ON-Ngn3 
 
MOI of 10 
 
 
 
---------- 
 
 
2) Add doxycycline to all wells (1µg/mL) 
Well#1: 
5x104 cells 
Negative control (no virus) 
 
 
Well#2: 
5x104 cells 
pTiger-Pdx1mRFP-Ins1eGFP 
MOI of 2 
Well#3: 
5x104 cells 
Positive control 
pTigerCMVeGFP 
MOI of 2 
Well#4: 
5x104 cells 
pTiger-Pdx1mRFP-Ins1eGFP 
L-Tet-ON-MafA 
L-Tet-ON-Pdx1 
L-Tet-ON-Pax6 
L-Tet-ON-Ngn3 
 
MOI of 2 
Well#5: 
5x104 cells 
pTiger-Pdx1mRFP-Ins1eGFP 
L-Tet-ON-MafA 
L-Tet-ON-Pdx1 
L-Tet-ON-Pax6 
L-Tet-ON-Ngn3 
 
MOI of 10 
 
 
 
---------- 
 
- Add each solution containing the viral particles into each well; 
- Incubate cells at 37ºC and 16 hours later replace medium for pancreatic induction 
medium: cells were cultured in N2B27 medium supplemented with 0.1 mM β-
mercaptoethanol (Invitrogen), 2 mM glutamine (Invitrogen), 1 mM MEM non-
essential aminoacids (Gibco), 0.5%BSA(Sigma), 1% B27 (Invitrogen), 20 ng/mL 
basic fibroblast growth factor (R&DSystem), and 1% insulin-transferrin-selenium 
(Invitrogen) to further encourage transdifferentiation; 
- Refresh medium every 48 hours. 
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After 21 days of in vitro cell culture, we looked for GFP and RFP positive cells, which 
are indicators of the reporter pTiger-Pdx1mRFP-Ins1eGFP activity. The positive control 
lentiviral vector pTigerCMVeGFP expressed GFP in both conditions (with doxycycline and 
without), as expected. However, there was neither GFP nor RFP activity in the reporter 
pTiger-Pdx1mRFP-Ins1eGFP, indicating that there was no activation of the both insulin and 
Pdx1 promoters. Although a week GFP signal was observed in Figures 20 and 21, we 
postulated that this could be due to a contamination, since the signal was detected both in the 
minus and plus Doxycycline conditions. This contamination might arose from the positive 
viral control pTigerCMVeGFP at the time of transduction.  
 
 
 
Figure 20: Effect of the ectopic expression of MafA, Pdx1, Pax6 and Ngn3 in the transdifferentiation of human 
dermal fibroblasts into the β-cell phenotype, after 21 days in culture without the addition of doxycycline in the 
medium. GFP expression indicates the reporter pTiger-Pdx1mRFP-Ins1eGFP activity. The top three panels are 
the negative and positive controls. The negative controls (No virus; pTiger-Pdx1mRFP-Ins1eGFP only) show no 
GFP activity, as expected. In the positive control (pTigerCMVeGFP) there is GFP expression. In the bottom two 
panels are the experimental conditions. A very few amount of cells expressed GFP. 
 
No Virus pTIGER-Pdx1mRFP-Ins1eGFP pTIGER CMVeGFP
pTIGER-Pdx1mRFP-Ins1eGFP pTIGER-Pdx1mRFP-Ins1eGFP
+ L-MAFA
+ L-PDX1
+ L-PAX6
+ L-NGN3
+ L-MAFA
+ L-PDX1
+ L-PAX6
+ L-NGN3
MOI-2
MOI-2 MOI-2
MOI-10
-DOX
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Figure 21: Effect of the ectopic expression of MafA, Pdx1, Pax6 and Ngn3 in the transdifferentiation of human 
dermal fibroblasts into the β-cell phenotype, after 21 days in culture with the addition of doxycycline (1µg/mL) 
into the medium. GFP expression indicates the reporter pTiger-Pdx1mRFP-Ins1eGFP activity. The top three 
panels are the negative and positive controls. The negative controls (No virus; pTiger-Pdx1mRFP-Ins1eGFP 
only) show no GFP activity, as expected. In the positive control (pTigerCMVeGFP) there is GFP expression. In 
the bottom two panels are the experimental conditions. A very few amount of cells expressed GFP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No Virus pTIGER-Pdx1mRFP-Ins1eGFP pTIGER CMVeGFP
+ L-MAFA
+ L-PDX1
+ L-PAX6
+ L-NGN3
+ L-MAFA
+ L-PDX1
+ L-PAX6
+ L-NGN3
MOI-2
MOI-2 MOI-2
MOI-10
+DOX
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3. DISCUSSION AND CONCLUSION 
 
This thesis is part of a larger project ongoing in the Molecular and Regenerative 
Medicine Laboratory at University of Algarve. The goal of the overall project is to develop a 
method to transdifferentiate adult human cells to pancreatic β-cells. The strategy chosen to 
achieve this is by forced over-expression of pancreas specific transcription factors. 
 
Direct transdifferentiation is the process by which a given cell type is driven to replace 
the underlying regulatory state that establishes and maintains its cellular phenotype for an 
alternative regulatory state that will establish a different cellular phenotype. The first report 
that such a process could be driven by transcription factors that act as 'master regulators' came 
in 1989 with the work of Weintraub et al. who demonstrated that over-expression of the 
muscle specific transcription factor MyoD was capable of activating the expression of muscle 
specific genes in a number of different cell types (Weintraub & Tapscott 1989). This report 
was eventually followed by others, in which transdifferentiation was demonstrated for a 
number of cellular transitions, which have been discussed in the introduction of this work. 
In particular, efforts have been made by multiple groups worldwide to develop 
transdifferentiation methods to create pancreatic β-cells for the treatment of diabetes. Most of 
these efforts have tested the use of one or a few pancreas specific transcription factors starting 
from a range of initial cell types and have been partially successful, as a number of groups 
have demonstrated the feasibility of obtaining insulin-producing cells (Zhou et al. 2008). 
However, the phenotype obtained still falls short of a fully complete beta cell phenotype, in 
particular regarding the ability of the transdifferentiated cells to sense glucose concentrations 
and to appropriately secrete insulin in response. To date, there has been no report of a 
systematic search for an optimized set of transcription factors capable of driving 
transdifferentiation to the beta cell fate. 
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Cloning a collection of transcription factors 
 
Such a project must start with the development of a collection of pancreas specific 
transcription factors clones into an appropriate vector. A review of the literature led to the 
identification of 22 transcription factors known to be involved in pancreatic development or 
function of pancreatic β-cells. We obtained these transcription factors from three sources:  
 
a) A commercial library of genes that are already available in pEntry vectors of the Gateway 
system. Of note, the availability of these clones invited the use of a strategy based on 
Gateway recombination technology. A second point to keep in mind is that all these clones 
lacked stop codons, as the library had been designed to create fusion protein expression 
vectors. 
 
b) An attempt was made to obtain beta cell specific genes directly from total RNA from 
human islet samples by RT-PCR 
 
c) A set of commercially available cDNA clones (complete with stop codons) in mammalian 
expression vectors.  
 
 
Choice of vector 
 
An important aspect of the projects design relates to the choice of delivery vector for 
the transcription factors. Such a delivery vector would need to be practical and efficient in 
terms of delivery, so a lentiviral vector was chosen. Lentiviral vectors have a carrying 
capacity of up to 8 Kb, which was more than sufficient for all our chosen transcription 
factors. In addition, they are capable of efficient transduction of both dividing and non-
dividing cells of various cell types.  
In addition, inducible expression was a desirable feature due to the necessity of 
ascertaining the phenotypic stability of any transdifferentiation we could obtain. By using an 
inducible expression vector, it would be possible to deliver the transcription factors to the 
initial cell type, turn on the expression to induce transdifferentiation, and eventually turn 
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expression off in order to determine if the new regulatory state could be sustained in the 
absence of expression of exogenous factors.  
All these characteristics are present in our lentiviral vector of choice, which contains 
all the elements required for doxycicline-regulated induction of expression. This lentiviral 
vector contains a TET-ON system, in which the transcription factor to be expressed is under 
the control of a TET-ON promoter. This promoter is only functional if a transactivator is 
expressed in the cell and if doxycicline is present in the cell culture medium. The lentiviral 
vector contains a constitutive promoter expressing the required transactivator.  
However, this lentiviral vector, being a complex construct, has multiple restriction 
enzyme sites, making cloning by traditional restriction enzyme cutting and T4 DNA ligase 
techniques challenging due to the scarcity of unique restriction sites in the appropriate 
positions.  
 
 
Cloning by Gateway recombination 
 
The availability of a number of transcription factors already cloned in pEntry vectors 
led us to attempt cloning by use of the Gateway recombination system. This required us to 
transform our lentiviral vector of choice into a Gateway destination vector by introducing a 
Gateway destination cassette at the appropriate position in the lentiviral vector. This was 
achieved by classic cloning in which the destination cassette was amplified incorporating 
MluI and EcoRV restiction sites into the forward and reverse primers. The fragment was 
cloned into a cloning vector and sequenced. In a second step, the MluI-EcoRV destination 
cassette was cloned into the vector similarly cut with MluI and EcoRV. 
 
The collection of clones in pEntry vectors (without stop codons) was sequenced to 
ensure they contained no mutations, and subjected to an LR recombination reaction for 
transfer into the destination vector. This strategy, while straightforward, was partially 
successful. Out of 9 clones we attempted to clone using this strategy we obtained 4 (IL-1, ISL-
1, NeuroD1 and MafA).  
Despite repeated attempts, we were unable to obtain correct clones for the remaining 5 
clopnes (Pax6, HADHB, PDX1, CDK4 and FBX32). The reason for this remains unclear, but 
is not unheard of when using Gateway technology.  
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In essence, the reaction employed is one of recombination and sensitive to the nature 
of the sequences involved in the reaction; we hypothesize that the unsuccessful clones 
underwent unwanted recombination reactions that resulted in clones with incorrect structure. 
 
In order to correct the sequence of the clones we had obtained in terms of 
reconstructing the missing stop codon, we utilized a commercially available strategy (Quick 
Change Mutagenesis Kit-Stratagene). This system consists in performing a PCR reaction 
using primers containing the mutations that one wants to introduce into the plasmid on an 
intact plasmid molecule. Successive rounds of PCR result in the amplification of a molecule 
with modified sequence. We partially corrected one of the clones (Lenti-TET-ON-NeuroD1) 
using this strategy. This clone awaits complete correction, as do the other three clones we 
obtained (IL1, ISL-1 and MafA). 
 
 
Cloning using the In-Phusion strategy 
 
We then attempted a different strategy: In-Phusion cloning. This approach involves 
mixing two fragments: a) the linearized vector and b) the insert that is to be cloned. Of note, 
both fragments need to have a sequence overlap of 15 bp at their respective ends, as explained 
in the results section. The Vvpol enzyme (derived from vaccinia virus) has a 3´to 
5´exonuclease activity and exposes variable length 5´overhangs at the ends of both fragments. 
Since the fragments posses 15 base overlaps of identical sequence, complementary overhangs 
are created, allowing the binding through base complementary of the fragments. These are 
transformed into bacteria and repaired in vivo by DNA nick repairing enzymes. 
Using this system, we successfully cloned four transcription factors (Ngn3, Pax6, 
Pdx1 and MafA) out of 11 attempted. Despite repeated attempt, the remaining factors could 
not be cloned. The reasons for this failure are unclear, but we suspect that the particular 
lentiviral backbone we have chosen to clone our transcription factors into is rather unstable. 
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A first attempt at transdifferentiation 
 
As the first four transcription factors (Ngn3, Pdx1, MafA and Pax6) became available 
we decide to attempt a transdifferentiation experiment. To do so, lentiviral preparations were 
made of the four lentiTET-ON TFs. The cells of choice were adult human fibroblasts obtained 
from a commercial vendor. The design involved co- transduction of the cells along with a 
reporter lentiviral vector carrying RFP under the control of a pdx1 promoter and GFP under 
the control of an insulin promoter. The rationale is that a transdifferentiation event would 
cause upregulation of fluorescence.  
However, no reporter activity was evident after three weeks of culture post-
transduction. Lack of transduction was not the cause, as a control lentiviral vector expressing 
GFP was capable of transducing cells. We conclude that this particular combination of 
transcription factors was incapable of transdifferentiation of human adult fibroblasts under the 
condition used. 
 
 
Future directions 
 
Despite intense work and repeated attempts, a number of transcription factors remain 
to be cloned. Success in this cloning effort is obviously crucial to the development of the 
project. We intend to obtain a different lentiviral vector backbone with the same 
characteristics (TET-ON system) which has a better set of available restriction sites for 
cloning and which will hopefully be more stable in cloning. 
 
Once a more complete set of transcription factors is obtained, attempts will be made to 
transduce several different cell types with a large collection of TFs in order to test for 
transdifferentiation. 
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